05:01 AM EST, 01/06/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.

Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.

The trial highlighted "neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis," the company said.